Elizabeth Trehu

Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55

Herbert Tilg, Elizabeth Trehu, MB Atkins et al. · Blood · 1994 · 794 citations · Full text

Life Sciences, Immunology, Pharmacology +14

Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Owen A. O’Connor, Craig H. Moskowitz, Jamie Muzzy et al. · Journal of Clinical Oncology · 2004 · 579 citations

Medicine, Hematology, Pharmacology +17

Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

André Goy, Anas Younes, Peter McLaughlin et al. · Journal of Clinical Oncology · 2004 · 527 citations · Full text

Medicine, Hematology, Pharmacology +15

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

Robert Z. Orlowski, Peter M. Voorhees, Reynaldo Garcia et al. · Blood · 2004 · 319 citations

Medicine, Oncology, Pharmacology +17

Bortezomib Therapy in Patients With Relapsed or Refractory Lymphoma: Potential Correlation of In Vitro Sensitivity and Tumor Necrosis Factor Alpha Response With Clinical Activity

Sandra J. Strauss, Lenushka Maharaj, Susan Hoare et al. · Journal of Clinical Oncology · 2006 · 171 citations · Full text

Medicine, Hematology, Oncology +17